3,3-dimethyl-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine | 1201013-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,3-dimethyl-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 3,3-dimethyl-5-[4-(trifluoromethyl)phenyl]-1,2-dihydropyrrolo[2,3-b]pyridine
• CAS: 1201013-96-8
• 化学式: C₁₆H₁₅F₃N₂
• 分子量: 292.304
• InChiKey: KOKNPKFYIDIQML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,3-dimethyl-5-(4-trifluoromethyl-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one 在 lithium aluminium tetrahydride 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 生成 3,3-dimethyl-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine
  参考文献：
  名称：

  [EN] ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  [FR] PYRROLIDINE SULFONAMIDES ANNELÉS AVEC GROUPEMENT DE TÊTE OXADIAZOLONE, PROCÉDÉS POUR LEUR PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS

  摘要：

  该发明涉及具有氧代噻唑酮基团的环戊胺磺胺衍生物及其生理上可接受的盐和生理功能衍生物，显示PPARδ或PPARδ和PPARα激动剂活性。所描述的化合物为公式（I）中的基团所定义的化合物，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的紊乱以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。

  公开号：

  WO2009149819A1

文献信息

• ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Keil Stefanie

  公开号：US20110207738A1

  公开（公告）日：2011-08-25

  The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及具有噁唑酮头基的环状吡咯烷磺酰胺及其生理上可接受的盐和生理上功能衍生物，其具有PPARdelta或PPARdelta和PPARalpha激动剂活性。所描述的是公式(I)中的化合物，其中基团如定义所述，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
  申请人：Sanofi

  公开号：US08329725B2

  公开（公告）日：2012-12-11

  The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及具有噁唑烷酮头基的环状吡咯烷磺酰胺及其生理上可接受的盐和生理上功能衍生物，具有 PPARδ 或 PPARδ 和 PPARα 激动剂活性。所描述的是式（I）化合物及其生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病的治疗。
• US8329725B2
  申请人：——

  公开号：US8329725B2

  公开（公告）日：2012-12-11
• [EN] ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLIDINE SULFONAMIDES ANNELÉS AVEC GROUPEMENT DE TÊTE OXADIAZOLONE, PROCÉDÉS POUR LEUR PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：SANOFI AVENTIS

  公开号：WO2009149819A1

  公开（公告）日：2009-12-17

  The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及具有氧代噻唑酮基团的环戊胺磺胺衍生物及其生理上可接受的盐和生理功能衍生物，显示PPARδ或PPARδ和PPARα激动剂活性。所描述的化合物为公式（I）中的基团所定义的化合物，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗相关的紊乱以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。